InvestorsObserver
Sign Up Login

RCKT Rocket Pharmaceuticals Inc

$9.94 $0.00 (0.00%)
Add to Watchlist Compare
Overall

RCKT Stock Analysis Overview

What this means: InvestorsObserver gives Rocket Pharmaceuticals Inc (RCKT) an overall rank of 32, which is below average. Rocket Pharmaceuticals Inc is in the bottom half of stocks based on the fundamental outlook for the stock and an analysis of the stock's chart. A rank of 32 means that 68% of stocks appear more favorable to our system.

Who this matters to: Overall Ranking is a comprehensive evaluation. It considers technical and fundamental factors and is a good starting point for evaluating a stock.

View Sample Report
Fundamental PREMIUM

RCKT Fundamental Analysis

Who this matters to: The Fundamental Ranking considers the health of the underlying company. It is best used by longer-term buy-and-hold investors.

Upgrade to Premium to unlock Fundamental Ranking

Short-Term Technical PREMIUM

RCKT Short-Term Technical Analysis

Who this matters to: The Short-Term Technical Ranking evaluates a stock’s trading over the past month. This is most useful for short- to medium-term stock and option traders.

Upgrade to Premium to unlock Short-Term Technical Ranking

Long-Term Technical PREMIUM

RCKT Long-Term Technical Analysis

Who this matters to: The Long-Term Technical Ranking is a good gauge of how a stock has traded over the past several months. This is useful for medium to long-term stock and option traders.

Upgrade to Premium to unlock Long-Term Technical Ranking

Analyst Ranking PREMIUM

RCKT Analyst Ranking

Who this matters to: Analyst Ranking shows you which stocks Wall Street analysts like the most. Since analysts build valuation models, this is most useful for medium to long-term investors who are interested in a valuation-based approach.

Upgrade to Premium to unlock Analyst Ranking Analysis

Valuation PREMIUM

RCKT Valuation Ranking Analysis

Who this matters to: Valuation Ranking is most-useful for value-focused investors who plan to hold a stock for the long term.

Upgrade to Premium to unlock Valuation Ranking

Stock Sentiment PREMIUM

RCKT Stock Sentiment Analysis

Who this matters to: Sentiment Rank looks at the past five trading days. This is our shortest-term evaluation and is best used by people with a very short horizon.

Upgrade to Premium to unlock Stock Sentiment Ranking

RCKT Stock Analysis Overview

What this means: InvestorsObserver gives Rocket Pharmaceuticals Inc (RCKT) an overall rank of 32, which is below average. Rocket Pharmaceuticals Inc is in the bottom half of stocks based on the fundamental outlook for the stock and an analysis of the stock's chart. A rank of 32 means that 68% of stocks appear more favorable to our system.

Who this matters to: Overall Ranking is a comprehensive evaluation. It considers technical and fundamental factors and is a good starting point for evaluating a stock.

Create a FREE account to see full RCKT report

RCKT Fundamental Analysis

Who this matters to: The Fundamental Ranking considers the health of the underlying company. It is best used by longer-term buy-and-hold investors.

Upgrade to Premium to unlock Fundamental Ranking

RCKT Short-Term Technical Analysis

Who this matters to: The Short-Term Technical Ranking evaluates a stock’s trading over the past month. This is most useful for short- to medium-term stock and option traders.

Upgrade to Premium to unlock Short-Term Technical Ranking

RCKT Long-Term Technical Analysis

Who this matters to: The Long-Term Technical Ranking is a good gauge of how a stock has traded over the past several months. This is useful for medium to long-term stock and option traders.

Upgrade to Premium to unlock Long-Term Technical Ranking

RCKT Analyst Ranking

Who this matters to: Analyst Ranking shows you which stocks Wall Street analysts like the most. Since analysts build valuation models, this is most useful for medium to long-term investors who are interested in a valuation-based approach.

Upgrade to Premium to unlock Analyst Ranking Analysis

RCKT Valuation Ranking Analysis

Who this matters to: Valuation Ranking is most-useful for value-focused investors who plan to hold a stock for the long term.

Upgrade to Premium to unlock Valuation Ranking

RCKT Stock Sentiment Analysis

Who this matters to: Sentiment Rank looks at the past five trading days. This is our shortest-term evaluation and is best used by people with a very short horizon.

Upgrade to Premium to unlock Stock Sentiment Ranking

Rocket Pharmaceuticals Inc (RCKT) Analyst Forecast

RCKT Price, Volume, Earnings, and Dividend Date

  • Last Price $9.94
  • Previous Close $9.94
  • Change $0.00
  • Open $10.26
  • Volume 531,300
  • Avg. Volume (100-day) 563,015
  • Market Cap 654,428,666
  • Days Range 9.7 - 10.7
  • 52-week Range 7.57 - 49.66
  • Dividend Yield —
  • Ex. Dividend Date —
  • P-E —
  • EPS —
  • Earnings Date 08/03/22
  • Sector Healthcare
  • Industry Biotechnology
  • Avg. Analyst Rec. Premium
  • Beta 2.709
  • PEG Ratio —

Rocket Pharmaceuticals Inc (RCKT) Company Description

Rocket Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It is focused on the development of gene therapies for rare and devastating pediatric diseases. The pipeline products of the company include RP-A501 for Danaon Disease, RP-L102 for Fanconi Anemia, RP-L201 for Leukocyte Adhesion, RP-L301 for Pyruvate Kinase Deficiency, and RP-L401 for Infantile Malignant Osteopetrosis.

Rocket Pharmaceuticals Inc (RCKT) Stock Chart

View Interactive RCKT chart

My Watchlists

Follow Your Favorite Stocks

Top Stocks in Biotechnology

Company Price
Liquidia Corp (LQDA) (LQDA) $5.61
Veru Inc (VERU) (VERU) $15.01
Concert Pharmaceutic (CNCE) (CNCE) $4.79
Arcutis Biotherapeutics Inc (ARQT) (ARQT) $19.50
Trevi Therapeutics Inc (TRVI) (TRVI) $2.24
Adma Biologics (ADMA) (ADMA) $2.01
Vaxcyte Inc (PCVX) (PCVX) $24.03
Fennec Pharmaceuticals Inc (FENC) (FENC) $5.97
Lyra Therapeutics Inc (LYRA) (LYRA) $5.61
Bellus Health Inc (BLU) (BLU) $8.80